KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Treasury Shares (2016 - 2025)

West Pharmaceutical Services' Treasury Shares history spans 17 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Treasury Shares rose 5.21% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 5.21%, while the annual FY2025 figure was $1.1 billion, 5.21% up from the prior year.
  • Treasury Shares for Q4 2025 was $3.3 million at West Pharmaceutical Services, down from $3.4 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.4 million in Q2 2025 and bottomed at $100000.0 in Q2 2022.
  • The 5-year median for Treasury Shares is $1.2 million (2021), against an average of $1.3 million.
  • The largest annual shift saw Treasury Shares skyrocketed 123.51% in 2024 before it increased 5.21% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $229.5 million in 2021, then soared by 61.61% to $370.9 million in 2022, then skyrocketed by 71.91% to $637.6 million in 2023, then soared by 65.79% to $1.1 billion in 2024, then rose by 5.21% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for WST's Treasury Shares are $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.1 billion (Q2 2025).